Skip to main content
  • RegMed XB welcomes new General Director, Bernard Mulder
06 Feb 2020


RegMed XB welcomes new General Director, Bernard Mulder

RegMed XB welcomes new General Director, Bernard Mulder

The Supervisory Board of RegMed XB is excited to announce the appointment of Bernard Mulder as General Director, effective March 1, 2020.

Bernard joins RegMed XB from Boehringer Ingelheim, where he led the Medical Affairs Department after more than two decades in medical, marketing, sales and management positions in the life sciences. He worked for Organon in Asia, Europe and the USA, ultimately as senior director of the Global Venture Team, and was Global VP Marketing, Sales and Business Development for Avantium Pharma.

In 2011, Bernard co-founded Eagle Rock Life Sciences to support life sciences enterprises from early start-ups to mature companies (hands-on). He earned his medical degree at Leiden University and an MBA from New York Institute of Technology.

We consider ourselves fortunate to have such an experienced innovator, coach and communicator willing to join and lead our team.

Bernard Mulder

Bernard will take over as General Director from Prof. Dr. Marianne van der Steen per 1 March 2020. We thank Marianne for her contribution to founding and setting up RegMed XB and are happy to announce that she will continue to serve on the Executive Board as New Business Development Director together with Frank Luyten (Medical Scientific Director) and Tom Oostrom (Patient Advocate).

Both Bernard and Marianne will engage with stakeholders in their new roles during RegMed XB’s Annual Meeting on 4-5 March in Utrecht. We look forward to the new momentum these appointments will bring to our quest to bring new regenerative medicine solutions to patients.

Have something to share?

Now you can contribute to keep our news section fresh and up-to date with relevant events and grants, research results and high impact publications related to REGMED XB’ Moonshots. Contributions can be sent to This email address is being protected from spambots. You need JavaScript enabled to view it.. Please submit the text in English and include a short title. We are looking forward to your input!